Non-celiac gluten hypersensitivity

What is all the fuss about?

Steffen Husby, Joseph A Murray

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Non-celiac gluten sensitivity (NCGS) has been introduced recently as a potentially common disease on the basis of studies of patients with claimed reactivity to gluten but without the characteristics of celiac disease (CD). CD is characterized by antibody reactivity toward the autoantigen transglutaminase 2, characteristic histological abnormalities of the small intestine, and an almost obligatory genetic haplotype (HLA-DQ2 or DQ8). The diagnosis of NCGS is based largely on the clinical suspicion of hyper-reactivity to gluten and the absence of the characteristics of CD. Few published studies have used double-blind placebo-controlled food challenges (DBPCFCs) for the diagnosis of NCGS, and none in children. Innate immune reactivity to amylase trypsin inhibitors has been suggested as the pathogenic principle in NCGS, but confirmatory evidence is lacking. Also, further clinical studies including DBPCFCs are needed.

Original languageEnglish (US)
Article number54
JournalF1000Prime Reports
Volume7
DOIs
StatePublished - May 12 2015

Fingerprint

Glutens
Hypersensitivity
Celiac Disease
Placebos
Food
Trypsin Inhibitors
Autoantigens
Amylases
Haplotypes
Small Intestine
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Non-celiac gluten hypersensitivity : What is all the fuss about? / Husby, Steffen; Murray, Joseph A.

In: F1000Prime Reports, Vol. 7, 54, 12.05.2015.

Research output: Contribution to journalArticle

@article{027dfba884ac4fca88bcd94074c080ad,
title = "Non-celiac gluten hypersensitivity: What is all the fuss about?",
abstract = "Non-celiac gluten sensitivity (NCGS) has been introduced recently as a potentially common disease on the basis of studies of patients with claimed reactivity to gluten but without the characteristics of celiac disease (CD). CD is characterized by antibody reactivity toward the autoantigen transglutaminase 2, characteristic histological abnormalities of the small intestine, and an almost obligatory genetic haplotype (HLA-DQ2 or DQ8). The diagnosis of NCGS is based largely on the clinical suspicion of hyper-reactivity to gluten and the absence of the characteristics of CD. Few published studies have used double-blind placebo-controlled food challenges (DBPCFCs) for the diagnosis of NCGS, and none in children. Innate immune reactivity to amylase trypsin inhibitors has been suggested as the pathogenic principle in NCGS, but confirmatory evidence is lacking. Also, further clinical studies including DBPCFCs are needed.",
author = "Steffen Husby and Murray, {Joseph A}",
year = "2015",
month = "5",
day = "12",
doi = "10.12703/P7-54",
language = "English (US)",
volume = "7",
journal = "F1000Prime Reports",
issn = "2051-7599",
publisher = "Faculty of 1000 Ltd",

}

TY - JOUR

T1 - Non-celiac gluten hypersensitivity

T2 - What is all the fuss about?

AU - Husby, Steffen

AU - Murray, Joseph A

PY - 2015/5/12

Y1 - 2015/5/12

N2 - Non-celiac gluten sensitivity (NCGS) has been introduced recently as a potentially common disease on the basis of studies of patients with claimed reactivity to gluten but without the characteristics of celiac disease (CD). CD is characterized by antibody reactivity toward the autoantigen transglutaminase 2, characteristic histological abnormalities of the small intestine, and an almost obligatory genetic haplotype (HLA-DQ2 or DQ8). The diagnosis of NCGS is based largely on the clinical suspicion of hyper-reactivity to gluten and the absence of the characteristics of CD. Few published studies have used double-blind placebo-controlled food challenges (DBPCFCs) for the diagnosis of NCGS, and none in children. Innate immune reactivity to amylase trypsin inhibitors has been suggested as the pathogenic principle in NCGS, but confirmatory evidence is lacking. Also, further clinical studies including DBPCFCs are needed.

AB - Non-celiac gluten sensitivity (NCGS) has been introduced recently as a potentially common disease on the basis of studies of patients with claimed reactivity to gluten but without the characteristics of celiac disease (CD). CD is characterized by antibody reactivity toward the autoantigen transglutaminase 2, characteristic histological abnormalities of the small intestine, and an almost obligatory genetic haplotype (HLA-DQ2 or DQ8). The diagnosis of NCGS is based largely on the clinical suspicion of hyper-reactivity to gluten and the absence of the characteristics of CD. Few published studies have used double-blind placebo-controlled food challenges (DBPCFCs) for the diagnosis of NCGS, and none in children. Innate immune reactivity to amylase trypsin inhibitors has been suggested as the pathogenic principle in NCGS, but confirmatory evidence is lacking. Also, further clinical studies including DBPCFCs are needed.

UR - http://www.scopus.com/inward/record.url?scp=84929457902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929457902&partnerID=8YFLogxK

U2 - 10.12703/P7-54

DO - 10.12703/P7-54

M3 - Article

VL - 7

JO - F1000Prime Reports

JF - F1000Prime Reports

SN - 2051-7599

M1 - 54

ER -